Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Swedish Orphan Biovitrum Ab (OP:BIOVF)

33.30 UNCHANGED
Last Price Updated: 9:30 AM EDT, Oct 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 33.30
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 33.30
Today's Range 33.30 - 33.30
52wk Range 25.80 - 33.30
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Merck Virus Treatment Shows 60.4% Effectiveness, Reduces Certain Infections In Infants
Merck announces positive results from Phase 2b/3 and interim Phase 3 trials of a monoclonal antibody designed to protect infants from RSV. 
Via Benzinga
Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases
Swedish Orphan Biovitrum and Apellis Pharmaceuticals released topline results from the Phase 3 VALIANT study of pegcetacoplan for C3 glomerulopathy and IC-MPGN. The study met primary and secondary... 
Via Benzinga

Performance

YTD
+17.7%
+17.7%
1 Month
+10.8%
+10.8%
3 Month
+14.9%
+14.9%
6 Month
+15.8%
+15.8%
1 Year
+5.7%
+5.7%

More News

Read More
Pfizer, Sanofi's Respiratory Syncytial Virus Products Faces Insurance And Logistical Hurdles To Protect Infants
Via Benzinga
Unanimous Support for AstraZeneca and Sanofi's Nirsevimab: Next Generation RSV Treatment on the Horizon
Via Benzinga
Apellis Pharma Flunks On Primary, Secondary Endpoints In Amyotrophic Lateral Sclerosis Study
Via Benzinga
Sanofi's Hemophilia Candidate Goes Under Priority FDA Review
Via Benzinga
ADC Therapeutics, Sobi Ink European Licensing Pact For Lymphoma Drug
Via Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
Via Benzinga
Why Shares of CTI BioPharma Are Soaring Wednesday
Via The Motley Fool
European Swedish Orphan Biovitrum To Acquire CTI BioPharma For $1.7B
Via Benzinga
Selecta, SOBI's Chronic Refractory Gout Program Meets Primary Goal, US Submission Expected Next Year
Via Benzinga
Veru Stock Could Retrace Week's 45% Gain As FDA Panel Votes Against COVID-19 Drug
Via Benzinga
Europe Approves AstraZeneca-Sanofi Partnered Antibody To Prevent RSV Infection In Infants
Via Benzinga
The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death
Via Benzinga
SOBI-Sanofi Partnered Hemophilia Therapy Shows Superior Bleed Protection Than Prior Prophylaxis
Via Benzinga
The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug
Via Benzinga
Sanofi-SOBI Hemophilia Candidate Aces Late-Stage Study In Pretreated Patients
Via Benzinga
Apellis - Sobi's Pegcetacoplan Wins European Approval For Rare Blood Disorder
Via Benzinga
AstraZeneca Blocks SOBI's $8B Buyout, Advent Withdraws The Bid - Report
Via Benzinga

Frequently Asked Questions

Is Swedish Orphan Biovitrum Ab publicly traded?
Yes, Swedish Orphan Biovitrum Ab is publicly traded.
What exchange does Swedish Orphan Biovitrum Ab trade on?
Swedish Orphan Biovitrum Ab trades on the OTC Traded
What is the ticker symbol for Swedish Orphan Biovitrum Ab?
The ticker symbol for Swedish Orphan Biovitrum Ab is BIOVF on the OTC Traded
What is the current price of Swedish Orphan Biovitrum Ab?
The current price of Swedish Orphan Biovitrum Ab is 33.30
When was Swedish Orphan Biovitrum Ab last traded?
The last trade of Swedish Orphan Biovitrum Ab was at 10/06/25 09:30 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.